# Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

> **NCT01562626** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Anaeropharma Science, Inc.** · enrollment: 75 (estimated)

## Conditions studied

- Tumors
- Neoplasms
- Cancer

## Interventions

- **DRUG:** APS001F
- **DRUG:** Flucytosine (5-FC)
- **DRUG:** 10% maltose

## Key facts

- **NCT ID:** NCT01562626
- **Lead sponsor:** Anaeropharma Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2012-09
- **Primary completion:** 2021-05
- **Final completion:** 2021-05
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2021-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01562626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01562626, "Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01562626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*